Sarepta Therapeutics (SRPT) Work In Process (2022 - 2026)

Sarepta Therapeutics' Work In Process history runs 5 years deep, the most recent figure standing at $981.0 million for Q1 2026.

• In Q1 2026, Work In Process rose 28.71% year-over-year to $981.0 million; the TTM figure through Mar 2026 stood at $981.0 million (up 28.71% YoY), while the FY2025 annual figure was $892.7 million, up 46.18% from the prior year.
• Work In Process for Q1 2026 stood at $981.0 million, up from $892.7 million in the prior quarter.
• The five-year high for Work In Process was $981.0 million in Q1 2026, with the low at $269.2 million in Q4 2022.
• The 5-year median for Work In Process is $686.5 million (2024), against an average of $647.5 million.
• The sharpest annual moves came in 2023 and 2024: Work In Process increased 18.3% in 2023, then jumped 91.77% in 2024.
• Sarepta Therapeutics' Work In Process stood at $269.2 million in 2022, then gained by 18.3% to $318.5 million in 2023, then surged by 91.77% to $610.7 million in 2024, then jumped by 46.18% to $892.7 million in 2025, then rose by 9.9% to $981.0 million in 2026.
• Business Quant data shows SRPT's Work In Process at $981.0 million in Q1 2026, $892.7 million in Q4 2025, and $885.4 million in Q3 2025.